CKD-602. Chong Kun Dang.

Mirjam, Crul

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2004

Data sources: Europe PubMed Central

CKD-602. Chong Kun Dang.

descriptionPublicationkeyboard_double_arrow_right Article 22 Mar 2004 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 4 (issn: 1472-4472,

Copyright policy )

Authors: Mirjam, Crul;

pmid: 14763132

CKD-602. Chong Kun Dang.

- Summary
- Subjects
- Metrics

Abstract

Chong Kun Dang is developing the camptothecin analog CKD-602 for the potential treatment of cancer. By August 2000, phase II trials of CKD-602 were underway.

Keywords

Clinical Trials as Topic, DNA Topoisomerases, Type I, Neoplasms, Animals, Humans, Technology, Pharmaceutical, Camptothecin, Drugs, Investigational, Topoisomerase I Inhibitors

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average